The popular diabetes and weight-loss drug semaglutide may lower the risk of dementia when taken by Type 2 diabetes patients, new research from the Case Western Reserve School of Medicine suggests.

In recent years, the popularity of weight-loss drugs like Ozempic and Wegovy has soared so dramatically that they’ve inspired new vocabulary, spurred global shortages, and prompted moral debates.

The new weight-loss tablet was developed in a lab and is based on “a type of β2 agonist.” As explained in the news release: ...

Amycretin, a new weight-loss treatment from Novo Nordisk, combines two hunger hormones, helping participants lose nearly ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

Newly discovered molecule rivals Ozempic in weight loss – with fewer side effects. Stanford researchers have identified a naturally occurring molecule that can suppress appetite and facilitate ...

Scientists have discovered a naturally occurring molecule that aids appetite control and weight loss so well, it may compete with popular GLP-1 agonists like Ozempic. It's called BRP (BRINP2 ...

Danish drugmaker Novo Nordisk is working to bring its blockbuster drug Ozempic to India “as soon as possible", Dr Yan Cai, ...

Anaturally occurring molecule identified by Stanford Medicine researchers appears similar to semaglutide — also known as Ozempic — in suppressing appetite and reducing body weight. Notably, testing in ...